KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Net Income (2016 - 2025)

Historic Net Income for Sarepta Therapeutics (SRPT) over the last 14 years, with Q2 2025 value amounting to $196.9 million.

  • Sarepta Therapeutics' Net Income rose 294857.59% to $196.9 million in Q2 2025 from the same period last year, while for Sep 2025 it was $355.7 million, marking a year-over-year increase of 19227.85%. This contributed to the annual value of $235.0 million for FY2024, which is 14382.98% up from last year.
  • Sarepta Therapeutics' Net Income amounted to $196.9 million in Q2 2025, which was up 294857.59% from $158.8 million recorded in Q4 2024.
  • In the past 5 years, Sarepta Therapeutics' Net Income registered a high of $196.9 million during Q2 2025, and its lowest value of -$516.8 million during Q1 2023.
  • For the 5-year period, Sarepta Therapeutics' Net Income averaged around -$72.2 million, with its median value being -$48.1 million (2021).
  • In the last 5 years, Sarepta Therapeutics' Net Income tumbled by 85615.14% in 2021 and then soared by 294857.59% in 2025.
  • Quarter analysis of 5 years shows Sarepta Therapeutics' Net Income stood at -$122.0 million in 2021, then rose by 9.94% to -$109.9 million in 2022, then soared by 141.44% to $45.5 million in 2023, then soared by 248.8% to $158.8 million in 2024, then increased by 24.02% to $196.9 million in 2025.
  • Its Net Income was $196.9 million in Q2 2025, compared to $158.8 million in Q4 2024 and $33.6 million in Q3 2024.